Hinge Health's 2026 Selling Season is Tracking Ahead of Prior Year Performance, Morgan Stanley Says

MT Newswires Live11-06

Hinge Health's (HNGE) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, Morgan Stanley said in Wednesday note.

Noting the company's Q3 results, Morgan Stanley said that the company's adjusted earnings before interest and taxes of $30.4 million was "meaningfully" above Wall Street estimate of $19 million, as investment in automation and artificial intelligence are driving "meaningful operating leverage".

Morgan Stanley also increased its 2025, 2026, and 2027 revenue estimates by 4%, 5%, and 5% respectively, and EBIT estimates by 33%, 25%, and 21%, respectively.

Morgan Stanley maintained its overweight rating on the stock and raised its price target to $72 from $67.

Price: 46.86, Change: -6.58, Percent Change: -12.31

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581777587?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 00:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581777587","market":"sh","top_or_hot":-1,"title":"Hinge Health's 2026 Selling Season is Tracking Ahead of Prior Year Performance, Morgan Stanley Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/HNGE\">Hinge Health</a>'s (HNGE) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in Wednesday note.</p><p>Noting the company's Q3 results, Morgan Stanley said that the company's adjusted earnings before interest and taxes of $30.4 million was \"meaningfully\" above Wall Street estimate of $19 million, as investment in automation and artificial intelligence are driving \"meaningful operating leverage\".</p><p>Morgan Stanley also increased its 2025, 2026, and 2027 revenue estimates by 4%, 5%, and 5% respectively, and EBIT estimates by 33%, 25%, and 21%, respectively.</p><p>Morgan Stanley maintained its overweight rating on the stock and raised its price target to $72 from $67.</p><p>Price: 46.86, Change: -6.58, Percent Change: -12.31</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hinge Health's 2026 Selling Season is Tracking Ahead of Prior Year Performance, Morgan Stanley Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHinge Health's 2026 Selling Season is Tracking Ahead of Prior Year Performance, Morgan Stanley Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-06 00:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/HNGE\">Hinge Health</a>'s (HNGE) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, <a href=\"https://laohu8.com/S/MTK\">Morgan Stanley</a> said in Wednesday note.</p><p>Noting the company's Q3 results, Morgan Stanley said that the company's adjusted earnings before interest and taxes of $30.4 million was \"meaningfully\" above Wall Street estimate of $19 million, as investment in automation and artificial intelligence are driving \"meaningful operating leverage\".</p><p>Morgan Stanley also increased its 2025, 2026, and 2027 revenue estimates by 4%, 5%, and 5% respectively, and EBIT estimates by 33%, 25%, and 21%, respectively.</p><p>Morgan Stanley maintained its overweight rating on the stock and raised its price target to $72 from $67.</p><p>Price: 46.86, Change: -6.58, Percent Change: -12.31</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1074936037.SGD","symbol_name":"JPMorgan Funds - US Value A (acc) SGD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2581777587","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581777587","pubTimestamp":1762361476,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hinge Health's (HNGE) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, Morgan Stanley said in Wednesday note.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU2023251221.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (USD) INC","LU2111349929.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AM\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1363072403.SGD":"Fidelity Global Financial Services A-ACC-SGD","BK4504":"桥水持仓","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1732800096.USD":"摩根大通环球收益基金A (irc)","BK4588":"碎股","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","LU0557290698.USD":"施罗德环球可持续增长基金","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0158827781.USD":" ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (USD) ACC","LU2028103732.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"AMG\" (USD) INC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","BK4196":"保健护理服务","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU0971096721.USD":"富达环球金融服务 A","LU1548497426.USD":"安联环球人工智能AT Acc","BK4581":"高盛持仓","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU0912757837.SGD":"JPMorgan Investment Funds - Global Income A (mth) SGD-H","LU0106831901.USD":"贝莱德世界金融基金A2","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU0882574139.USD":"富达环球消费行业基金A ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","BK4534":"瑞士信贷持仓","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU1668664300.SGD":"Blackrock World Financials A2 SGD-H","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","BK4127":"投资银行业与经纪业","HNGE":"Hinge Health, Inc.","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU2089284900.SGD":"Allianz Global Sustainability Cl AM Dis H2-SGD","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","BK4516":"特朗普概念","LU2271345857.HKD":"ALLIANZ GLOBAL SUSTAINABILITY \"AT\" (HKD) ACC","LU1244550577.SGD":"FTIF - Franklin Global Multi-Asset Income A (Mdis) SGD-H1"},"translate_title":"摩根士丹利表示，Hinge Health 2026年销售季的表现领先于上一年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HNGE":1.5},"content_text":"Hinge Health's (HNGE) 2026 selling season is tracking ahead of prior year performance, with majority of client additions in Q4 scheduled to launch in early 2026, Morgan Stanley said in Wednesday note.Noting the company's Q3 results, Morgan Stanley said that the company's adjusted earnings before interest and taxes of $30.4 million was \"meaningfully\" above Wall Street estimate of $19 million, as investment in automation and artificial intelligence are driving \"meaningful operating leverage\".Morgan Stanley also increased its 2025, 2026, and 2027 revenue estimates by 4%, 5%, and 5% respectively, and EBIT estimates by 33%, 25%, and 21%, respectively.Morgan Stanley maintained its overweight rating on the stock and raised its price target to $72 from $67.Price: 46.86, Change: -6.58, Percent Change: -12.31","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581777587","isCrawlerRequest":true}